



# STUDY OF PROTEIN - CIN CHILDREN WITH NEPHROTIC SYNDROME

Thesis

Submitted for the Partial Fulfilment of the Ph. Degree in Medical Childhood Studies

818. 32061

Gernal M. Hagrus

M.B., B. Ch., MSc (Pediatric)

Supervisors

53014

lo

*Prot.0r.* Mohamed Abd El-Kader Sobh - Magdy Zaki El-Ghamnam

Professor of Nephrology Institute of Urology & Nephrology Mansoura - University Assis. Professor of Clinical Pathology Faculty of Medicine

Faculty of Medicine Al-Azhar - University

Dr.

Hayam Kamal Nazef

Lecture in Medical Department Institute of Postgraduate Childhood Studies

Ain Shams - University

1997



Institute of Postgraduate Childhood Studies Medical Department Ain Shams University

# STUDY OF PROTEIN - C IN CHILDREN WITH NEPHROTIC SYNDROME

Thesis
Submitted for the Partial Fulfilment
of the Ph. Degree in Medical Childhood Studies

By

Gamal M. Hagras M.B., B. Ch., MSc (Pediatric)

#### Supervisors

Prof.Dr. Dr.
Mohamed Abd El-Kader Sobh Magdy Zaki El-Ghannam

Professor of Nephrology Institute of Urology & Nephrology Mansoura - University Assis. Professor of Clinical Pathology Faculty of Medicine Al-Azhar - University

Dr. Hayam Kamal Nazef

Lecture in Medical Department Institute of Postgraduate Childhood Studies Aln Shams - University

1997



بسم الله الرحمن الرحيم

## Acknowledgment

I would like to express my deepest feeling & sincere gratitude to *Professor Dr. Mohamed. Abd El-Kader Sobh.*, Professor & Head of Nephrology Department, Faculty of Medicine, Mansoura University, *Prof. Dr. Magdy Zaki El-Ghanam* Ass. Prof. of Clinical Pathology. Faculty of Medicine Al-Azhar University & *Dr. Hayam Kamal Nasef* Lecture in Medical Department, institute of Postgraduate childhood studies Ain-Shams University. For constant support, supervision, encouragement & valuable help & guidance during this study.

I would like to express my thanks to **Prof.Dr. Bothina Labib** for her kind help, encouragement & support in completion of this work.

Contents	Page
I - Inroduction & Aim of the Work	4
II- Review of Literature	••
Chapter (1):	
* Blood Coagulation	5 - 7
* Natural inhibitors of coagulation	
Chapter (2): Protein - C	
* Biochemistry & structure	9
* Synthesis of protein - C	10 - 11
* Activation of protein - C	12 - 14
* Protein - C inhibitors	15 - 17
* Mechanism of action of activated protein - C	
* Co - Factors of P - C	
Chapter (3) : Clinical aspects of protein - C.	
* Congenital protein - C deficiency	27 - 33
* P - C & purpura fulminans	
* P - C deficiency & D.I.C	. 36 - 38
* P - C & liver diseases	39 - 40
* P - C & surgery	. 41 - 42
* P - C & other clinical conditions	
* P - C & drugs	
Chapter (4):	
* Nephrotic syndrome	50 - 64
Chapter (5):	
* Nephrotic syndrome & protein - C	65 - 73
III - Subjects & Methods	74 - 87
IV - Statistical analysis	88 - 91
V - Reculte	92 - 128

	Page
VI - Discussion.	129 - 136
VII - Conclusion & Recommendation	137
VIII - English summary	138 - 139
IX - References	140 - 163
X - Arbic Summary	164 - 165

### List of Abbreviation

Ag. Antigen.

APC Activated protein - C

AT - III Antithrombin - III

AVH Acute viral hepatitis

DAVP D - Arginine vasopressin

DIC Dissiminated intravscular coagulation

DVT Deep vien thrombosis

FDPs Fibrin degradation products

FFP Fresh frozen pkasma

GLa Gamma carboxy glutamic acid

Hep G2 Human hepatoma cell line

PA plasminogen activator

PAI Plasminogen activator inhibitor

P- C Protein - C

PCI Protein - C inhibitor

P.T. Prothrombin time

MCNS Minimal change nephrotic syndrome

N.S. Nephrotic syndrome.

SDS Sodium dodecyl sulphate

TTP Thrombocytopenic purpura

## List of Tables

Tab.(1): Causes of nephrotic syndrome & the relative frequency in children
Tab.(2): The studied groups105
Tab.(3): Results of some haematological investigations in the studied groups106
Tab.(4): Results of some haematological inveestigations of group I in comparison to group II107
Tab.(5): Results of some hemostatic investigations in the studied groups
Tab.(6): Results of some hemostatic investigations of group I in comparison to group II109
Tab.(7): Results of some fibrinolytic investigations in the different groups
Tab.(8): Results of some fibrinolytic investigation of group I in comparison to group II111
Tab.(9): Results of serum albumin & protein in the different studied groups
Tab.(10): Results of protein - C Ag. & Activity of the different groups
Tab.(11): Results of protein - C of group I in comparison to group II
Tab.(12): Correlation studied of protein - C (Ag. & activity) with total serum protein, albumin, AT - III Ag%, AT-III conc. Plasmingen & fibringen.

# List of Figures

Fig.(1) :	Pathways of coagulation and catalytic features7
Fig.(2)	Structural of P - C11
Fig.(3) :	Schematic model for (in vivo) P - C activation14
Fig.(4) :	Approach to the child with nephrotic syndrome53
Fig.(5) :	Standard curve of protein - C concentration83
Fig.(6) :	Standard curve of protein - C activity87
Fig.(7) :	Mean platelet count in different groups116
Fig.(8) :	Mean bleeding time in different groups117
Fig.(9) :	Mean coagulation time in different groups118
Fig.(10):	Mean APTT in different groups119
Fig.(11):	Mean prothrombin time in different groups 120
Fig.(12):	Mean fibrinogen level among different groups121
Fig.(13):	Mean plasminogen level among different groups 122
Fig.(14):	Mean AT-III level among different groups123
Fig.(15):	Mean A-T-III concentration among different
	groups
Fig.(16):	Mean total protein level among different groups.125
Fig.(17):	Mean serum albumin level among different
	groups 126
Fig.(18):	Mean protein - C level among different groups 127
Fig.(19):	Mean protein - C activity among different
	groups128

# Introduction & Aim of Work

## Introduction & Aim of Work


Protein C is an anticoagulant protein which plays an important role in regulating blood coagulation in vivo. It is a vitamin K - dependent glycoprotein which is synthesized in the liver. The anticoagulant effect of protein C is due to inactivation of the activated FV & VIII. In order to exert this anticoagulant activity, protein C (which circulates in the blood as a zymogen) first has to be converted to the proteolytically active form in the presence of calcium & phospholipid (Esmon & Esmon, 1984).

In addition to its anticoagulant properties, protein C facilitate fibrinolysis (Fair & Marlar, 1986).

Hereditary or acquired protein C deficiency is associated with a predisposition to thromboembolic diseases so, preventive measures should be instituted. In nephrotic patients, many factors contribute to hypercoagulability & thromboembolic complications including At III def, increase concentration of fibrinogens, FV, VIII & platelets hypercoagulability (Abdullah, 1988).

The aim of our study was to estimate P - C quantity & quality in the blood of nephrotic patients for the possible role that it might play in the pathogenesis of thromboembolic complications in these patients & trial to find correlations between P - C & some hemostatic parameters.

# Review of Literature



#### **Bood Coagulation**

The haemostatic mechanism comprises a series of integrated reactions of the vessel wall, platelets, plasma coagulation and fibrinolytic factors directed towards maintenance or reestablishment of vascular integrity. It is a delicate balanced system influenced by vessel size, conditions of blood flow, inherited or acquired alternations of the concentrations, of coagulation, fibrinolytic & inhibitors factors, present in normal plasma or associated with a variety of pathologic conditions. Variation in any of these factors may lead to either excossive bleeding or thrombosis. Haemostasis & thrombosis may thus be looked on as the response of blood to vascular injury. So the functions of the normal haemostatic process are to prevent blood loss from intact vessels & to arrest bleeding rrom injured vessels (Wintrobe et al., 1981).

Blood coagulation has long been considered to be an enzymatic process, according to the coagulation cascade or waterfall hypothesis ( Davie and Ratnoff, 1994) most of the coagulation factors circulate as proenzymes which are converted to enzymes during the clotting process. The most obvious exception is fibrinogen, which is converted to insoluble fibrin in the final step. The function of each enzyme formed is to activate the proenzyme which succeeds it in the coagulation sequence.

The coagulation is initiated by two fundamental different mechanisms: The process of contact activation and the action of tissue factor, which proceed via two separate pathways (intrinsic & extrinsic pathways). The end result is factor X - activation. Then they converge by activating a third common pathway leading to fibrin formation (Fig. 1).

#### N.B: -

 The coagulation intrinsic & extrinsic system terms are widely used with reference to the reactions indicated by